Korea / Samsung Bioepis Goes Down Under; Blockchain-Based Vaccine Certificates; The First Korean Blockbuster?
The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown…
Boryung Pharm.
Last updated: 20.01.2015
One of the leading pharmaceutical companies in Korea, has created its own history: Boryung Pharm., as a parent company of Boryung Pharmaceutical Group, has been founded in 1963 after opening Boryung Pharmacy in 1957, and solidified its leadership position as a herb medicine manufacturer. From the year 1967 with Yongkaksan, Kushim, Gelfos and Kiungwhan, the legend recognized by all people have been created. Lately by developing and exporting new drugs such as Doxorubicin HCl and Fimasartan which are developed by our own technology, Boryung Pharm. is playing a major role as a principal axis power in the globalization of Boryung Pharmaceutical Group. Boryung Pharm., one of the 10 best pharmaceutical companies in Korea, is contributing to human health by manufacturing and launching on the market with 300 ethical products and 60 OTC products based on the initiative of Boryung R&D Institute.
Related
Joong Myung Cho – Chairman & CEO, CrystalGenomics, South Korea
Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery…
Young-Shik Cho – Chairman, SD Biosensor
Young-Shik Cho, chairman of SD Biosensor, recounts his journey leading diagnostics companies and expanding their…
Precision Medicine / Reclaiming Asia's Genomic Destiny
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome…
Jeong-Sun Seo – Chairman, Macrogen & President, KoreaBIO
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO),…
Sangrae Cho – CEO, Gencurix
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae…
Yeul-Hong Kim – Director, K-MASTER, South Korea
Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data…
M&A / Korean Celltrion Makes First Big Global Move with Acquisition of Takeda APAC Assets
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the…
SCM Lifescience / A Global Approach to Korean Regenerative Medicine
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in…
Jisoo Pae – CEO, Genome & Company
Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr…
Rare Diseases / Korean Corestem Targets US Market for Ground-Breaking ALS Treatment
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea,…
Kyung Suk Kim – CEO, Corestem
Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic…
